Molecular systems evaluation of oligomerogenic APPE693Q and fibrillogenic APPKM670/671NL/PSEN1Δexon9 mouse models identifies shared features with human Alzheimer's brain molecular pathology

Molecular Psychiatry

Volumn 21, Issue 8, 2016, Pages 1099-1111

  Readhead, B ^a   Haure Mirande, J V ^a   Zhang, B ^a   Haroutunian, V ^a,b   Gandy, S ^a,b,c   Schadt, E E ^a   Dudley, J T ^a   Ehrlich, M E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL FOOTBALL LEAGUE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; MUTANT PROTEIN; OLIGOMER; TRANSCRIPTOME; FIBRILLAR COLLAGEN; FMR1 PROTEIN, MOUSE; PRESENILIN 1;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BRAIN TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOSKELETON; DENTATE GYRUS; ENTORHINAL CORTEX; EPIGENETICS; EVALUATION STUDY; EXON; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENOME ANALYSIS; MALE; MOLECULAR PATHOLOGY; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEURITE; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; TRANSCRIPTOMICS; TRANSGENIC MOUSE; WILD TYPE MOUSE; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FIBRILLAR COLLAGENS; FRAGILE X MENTAL RETARDATION PROTEIN; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NEUROGENESIS; NEURONS; PLAQUE, AMYLOID; PRESENILIN-1; RISK FACTORS; TRANSCRIPTOME;

EID: 84946762413     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.167     Document Type: Article

References (89)

1. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009; 461: 218-223.
2. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 1996; 103: 455-490.
3. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-116.
4. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-127.
5. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013; 153: 707-720.
6. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 2010; 68: 220-230.
7. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248: 1124-1126.
8. Price KA, Varghese M, Sowa A, Yuk F, Brautigam H, Ehrlich ME, et al. Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-beta oligomers and no plaque pathology. Mol Neurodegener 2014; 9: 41.
9. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-Amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159-170.
10. Lopez-Gonzalez I, Schluter A, Aso E, Garcia-Esparcia P, Ansoleaga B, LL F, et al. Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol 2015; 74: 319-344.
11. Kim SH, Steele JW, Lee SW, Clemenson GD, Carter TA, Treuner K, et al. Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Abeta oligomer mouse. Mol Psychiatry 2014; 19: 1235-1242.
12. Sebollela A, Mustata GM, Luo K, Velasco PT, Viola KL, Cline EN, et al. Elucidating molecular mass and shape of a neurotoxic Abeta oligomer. ACS Chem Neurosci 2014; 5: 1238-1245.
13. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002; 30: 552-557.
14. Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher JP. Calculating sample size estimates for RNA sequencing data. J Comput Biol 2013; 20: 970-978.
15. Mouse Genome Sequencing C, Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420: 520-562.
16. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29: 15-21.
17. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-And-vote. Nucleic Acids Res 2013; 41: e108.
18. Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-930.
19. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate - A practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995; 57: 289-300.
21. Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 2009; 10: 161.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
23. Miller JA, Cai C, Langfelder P, Geschwind DH, Kurian SM, Salomon DR, et al. Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics 2011; 12: 322.
24. Chen EY, Xu H, Gordonov S, Lim MP, Perkins MH, Ma'ayan A. Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers. Bioinformatics 2012; 28: 105-111.
25. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma'ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 2010; 26: 2438-2444.
26. Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE Mouse Genome Database G. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res 2015; 43: D726-D736.
27. Carlson M, Falcon S, Pages H, Li N. org.Hs.eg.db: Genome wide annotation for Human, 2013.
28. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data. Genome Res 2012; 22: 2008-2017.
29. Berkeley CA. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. E-book available at: http://www.bepress. com/sagmb/vol3/iss1/art3, 2004.
30. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014; 15: R29.
31. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
32. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29.
33. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014; 42: D199-D205.
34. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
35. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 2004; 101: 2173-2178.
36. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70: 462-473.
37. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics 2008; 33: 240-256.
38. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-Amyloid mediates microglial activation. J Neurosci 2003; 23: 2665-2674.
39. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-Amyloid fibrils. Am J Pathol 2002; 160: 101-112.
40. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar betaamyloid through a beta1 integrin-dependent mechanism. J Neurosci 2004; 24: 9838-9846.
41. Chouraki V, De Bruijn RF, Chapuis J, Bis JC, Reitz C, Schraen S, et al. A genome-wide association meta-Analysis of plasma Abeta peptides concentrations in the elderly. Mol Psychiatry 2014; 19: 1326-1335.
42. Gartner U, Holzer M, Arendt T. Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience 1999; 91: 1-5.
43. Poduslo SE, Huang R, Huang J, Smith S. Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 50-55.
44. Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet 2006; 78: 78-88.
45. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 2007; 5: e52.
46. Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, Gagliani MC, et al. Amyloid precursor protein and Presenilin1 interact with the adaptor GRB2 and modulate ERK 1, 2 signaling. J Biol Chem 2007; 282: 13833-13844.
47. Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 2006; 281: 20315-20325.
48. Ghersi E, Noviello C, D'Adamio L. Amyloid-beta protein precursor (AbetaPP) intracellular domain-Associated protein-1 proteins bind to AbetaPP and modulate its processing in an isoform-specific manner. J Biol Chem 2004; 279: 49105-49112.
49. Yun SM, Cho SJ, Song JC, Song SY, Jo SA, Jo C, et al. SUMO1 modulates Abeta generation via BACE1 accumulation. Neurobiol Aging 2013; 34: 650-662.
50. Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 2007; 27: 3769-3779.
51. Bradley WD, Koleske AJ. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. J Cell Sci 2009; 122: 3441-3454.
52. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 2011; 3: pii: a004952.
53. Synapse. Accelerating Medicines Partnership (AMP) Alzheimers Disease Knowledge Portal. https://www.synapse.org/#!Synapse: syn2580853/wiki/10.7303/.syn2580853, 2015.
54. Lansbergen G, Akhmanova A. Microtubule plus end: a hub of cellular activities. Traffic 2006; 7: 499-507.
55. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
56. Morris JH, Kuchinsky A, Ferrin TE, Pico AR. enhancedGraphics: a Cytoscape app for enhanced node graphics. F1000Res 2014; 3: 147.
57. Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, Salamat MS, et al. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PloS One 2011; 6: e26549.
58. Renoux AJ, Carducci NM, Ahmady AA, Todd PK. Fragile X mental retardation protein expression in Alzheimer's disease. Front Genet 2014; 5: 360.
59. Orlov SV, Kuteykin-Teplyakov KB, Ignatovich IA, Dizhe EB, Mirgorodskaya OA, Grishin AV, et al. Novel repressor of the human FMR1 gene - identification of p56 human (GCC)(n)-binding protein as a Kruppel-like transcription factor ZF5. FEBS J 2007; 274: 4848-4862.
60. Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, et al. Diabetesassociated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci 2010; 30: 13110-13115.
61. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/.enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 2008; 283: 30919-30932.
62. Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 2015; 518: 365-369.
63. Yu L, Chibnik LB, Srivastava GP, Pochet N, Yang J, Xu J, et al. Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol 2015; 72: 15-24.
64. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci 2014; 17: 1164-1170.
65. Lendvai D, Morawski M, Negyessy L, Gati G, Jager C, Baksa G, et al. Neurochemical mapping of the human hippocampus reveals perisynaptic matrix around functional synapses in Alzheimer's disease. Acta Neuropathol 2013; 125: 215-229.
66. Vegh MJ, Heldring CM, Kamphuis W, Hijazi S, Timmerman AJ, Li KW, et al. Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer's disease. Acta Neuropathol Commun 2014; 2: 76.
67. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 2010; 30: 4833-4844.
68. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. A disintegrinmetalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004; 113: 1456-1464.
69. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense mutations potentiate beta-Amyloid accumulation by impairing prodomain chaperone function. Neuron 2013; 80: 385-401.
70. Tremblay MA, Acker CM, Davies P. Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimer's Dis 2010; 19: 721-733.
71. Gandy S, Heppner FL. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron 2013; 78: 575-577.
72. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-Analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-1458.
73. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78: 631-643.
74. Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, et al. CD45 opposes beta-Amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-Activated protein kinase. J Neurosci 2000; 20: 7587-7594.
75. Ebner F, Brandt C, Thiele P, Richter D, Schliesser U, Siffrin V, et al. Microglial activation milieu controls regulatory T cell responses. J Immunol 2013; 191: 5594-5602.
76. Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K, et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 2015; 85: 534-548.
77. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 2015; 85: 519-533.
78. Tone M, Powell MJ, Tone Y, Thompson SA, Waldmann H. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol 2000; 165: 286-291.
79. Docagne F, Gabriel C, Lebeurrier N, Lesne S, Hommet Y, Plawinski L, et al. Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J 2004; 383: 393-399.
80. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the beta-Amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 2004; 24: 865-874.
81. Heicklen-Klein A, Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 2000; 75: 1408-1418.
82. Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH. Short-Term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiol Aging 2013; 34: 2421-2430.
83. Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep 2015; 10: 633-644.
84. Burns TC, Li MD, Mehta S, Awad AJ, Morgan AA. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: A systematic bioinformatics-based critique of preclinical models. Eur J Pharmacol 2015; 759: 101-117.
85. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-Analysis. JAMA 2015; 313: 1924-1938.
86. Sevigny J, Chiao P, Williams L, Chen T, Ling Y, OGorman J, et al. Randomized, Double-blind, Placebo-controlled, Phase 1b Study of Aducanumab (BIIB037), an Anti-Aβ Monoclonal Antibody, in Patients With Prodromal or Mild Alzheimers Disease: Interim Results by Disease Stage and ApoE e4 Status. 67th Annual Meeting of the American Academy of Neurology 18-25 April 2015, Washington DC.
87. Gandy S. Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. N Engl J Med 2012; 367: 864-866.
88. Gandy S. Perspective: prevention is better than cure. Nature 2011; 475: S15.
89. Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med 2013; 64: 367-383.